Families affected by Huntington’s disease gained a rare reason for optimism on June 17, 2026, when uniQure N.V. disclosed that the U.S. Food and Drug Administration had reversed a previous position and agreed that existing clinical data on AMT-130 could serve as the primary basis for a future biologics license application. The shift came just months after the agency told the company its Phase I/II data package was “unlikely” to support approval. If the BLA moves forward, AMT-130 would become the first gene therapy cleared for the inherited neurodegenerative disorder, which affects roughly 30,000 people in the United States and has no approved disease-modifying treatment.
Why the FDA’s reversal on AMT-130 matters right now
The tension behind this story is straightforward: the FDA told uniQure one thing in December 2025 and said something materially different a few months later. According to the company’s March 2026 filing, pre-BLA meeting minutes issued in December 2025 stated that the Phase I/II data package was “unlikely” to support a biologics license application. That language carried real consequences: it signaled that uniQure would need a larger, longer confirmatory trial before seeking approval, adding years and hundreds of millions of dollars to the development timeline.
The company requested a Type A meeting with the FDA in January 2026, a procedural step reserved for urgent regulatory disputes. The agency had earlier conducted a Type B meeting that produced alignment on two key design elements: the use of natural-history external controls and the composite Unified Huntington’s Disease Rating Scale, known as cUHDRS, as the primary efficacy endpoint. What changed between December and the subsequent discussions was the company’s presentation of updated, longer-term data from both its U.S. and European trials. The working hypothesis is that AMT-130’s effect on cUHDRS decline, measured against external natural-history benchmarks, crossed a threshold the agency had previously set but that shorter follow-up had not yet reached.
For patients and their families, the practical difference is stark. Without this reversal, the path to an approved gene therapy for Huntington’s disease would have stretched well into the next decade. With it, a BLA submission could come within the next year or two, depending on how quickly uniQure assembles the full application package.
Three-year trial data and the cUHDRS endpoint that shifted FDA’s view
AMT-130 is a one-time injection of an adeno-associated virus serotype 5 vector carrying a micro-RNA designed to silence the mutant huntingtin gene. The therapy is delivered directly into the brain through a neurosurgical procedure. Two parallel studies form the clinical evidence base. The U.S. Phase I/II study enrolled adults with early manifest Huntington’s disease and randomized them to AMT-130 or a sham surgical procedure. A European companion trial followed a broadly similar design with some protocol differences to account for regulatory requirements across the Atlantic.
The cUHDRS endpoint combines motor, cognitive, and functional measures into a single score. In Huntington’s disease, this composite score declines predictably over time, and the rate of that decline has been well characterized in natural-history cohorts such as Enroll-HD. The FDA’s earlier Type B meeting alignment on this endpoint and on external controls meant the agency was willing, in principle, to accept a comparison between treated patients and historical decline rates rather than demanding a traditional placebo-controlled Phase III trial. The December 2025 assessment, however, found the available data insufficient to clear that bar.
Three-year follow-up data from both trials appear to have changed the calculus. While full efficacy and safety tables have not been published in a peer-reviewed journal or posted to ClinicalTrials.gov, the company’s SEC disclosures indicate the FDA agreed that the existing data “may serve as the primary basis” for a future BLA. That language, described in the March 2026 quarterly report and reiterated in subsequent investor communications, represents a significant upgrade from the December 2025 position.
The distinction between “unlikely to support” and “may serve as the primary basis” is not semantic. The first phrase effectively blocks a filing; the second opens the door to one. For a disease with no approved gene therapy and limited treatment options, that shift carries weight for the entire Huntington’s research community.
What gaps remain before AMT-130 reaches patients
Several questions remain open despite the FDA’s changed position. The full text of neither the December 2025 pre-BLA meeting minutes nor the January 2026 Type A meeting minutes is publicly available. Investors and clinicians are relying on uniQure’s own summary of those interactions, filed with the Securities and Exchange Commission, rather than on primary FDA documents. That leaves some uncertainty about the exact evidentiary standard the agency will apply when a BLA is formally submitted.
Key unknowns include how the FDA will weigh durability of effect, variability between the U.S. and European cohorts, and the safety profile of a one-time neurosurgical gene therapy. Three-year data offer a more reassuring window than earlier snapshots, but Huntington’s is a lifelong condition, and both efficacy and safety will need to be monitored over many years. Post-marketing commitments, if AMT-130 is approved, are likely to be extensive.
Another unresolved issue is how external control data will be operationalized in the BLA. Natural-history cohorts can differ in subtle ways from trial populations, including in age, baseline severity, and concomitant medications. The FDA’s willingness to consider such controls in principle does not eliminate the need for careful statistical adjustment and sensitivity analyses. Those details will matter for how confidently clinicians can interpret any apparent slowing of cUHDRS decline.
Access and implementation also loom as practical hurdles. AMT-130 requires specialized neurosurgical expertise and infrastructure that are concentrated in major academic centers. Even if the therapy wins approval, scaling delivery to patients across the United States and other regions will demand training, investment in surgical suites, and coordination among neurologists, neurosurgeons, and genetic counselors. Payers will face difficult decisions about how to reimburse a high-cost, one-time intervention on the basis of data that, while promising, are still derived from relatively small early-phase trials.
For families living with Huntington’s disease, the FDA’s reversal is therefore best understood as a pivotal step rather than a final victory. It shortens the regulatory path and signals that the agency sees a plausible case for approval grounded in existing data. Yet it does not guarantee a positive outcome, nor does it resolve broader questions about long-term benefit, equitable access, and how healthcare systems will absorb the logistical demands of gene therapy.
Still, in a field marked by decades of disappointment, the prospect that current AMT-130 data could underpin a BLA within the next couple of years represents a meaningful shift. The coming period-during which uniQure prepares its submission and the FDA refines its expectations-will determine whether that shift translates into the first approved gene therapy for Huntington’s disease or becomes another near-miss in a long and difficult search for disease-modifying treatments.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
